Press release
Presbyopia Pipeline Insight Expands as 10+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio
Presbyopia - Pipeline Insight, 2026
DelveInsight's "Presbyopia - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies developing several pipeline drugs in the Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Presbyopia treatment landscape. Learn more about the evolving Presbyopia pipeline today @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Presbyopia Pipeline Report
*
In February 2026, Viatris Inc. (Nasdaq: VTRS) announced that the Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026.
*
In January 2026, Yuvezzi (carbachol and brimonidine tartrate) received approval as an ophthalmic solution for the treatment of presbyopia.
*
In October 2024, the FDA accepted the New Drug Application (NDA) for LNZ100 (aceclidine eye drop) submitted by LENZ Therapeutics for the treatment of presbyopia - a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The FDA assigned a PDUFA target action date of August 8, 2025 for LNZ100.
*
DelveInsight's Presbyopia Pipeline Insight report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Presbyopia treatment.
*
The leading Presbyopia companies include Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.
*
Promising Presbyopia therapies include LX-OPH-162, Research programme, STN 1013600, GLK-302, Nyxol, VTI-001, LNZ100, MicroLine (Pilocarpine Ophthalmic), CSF-1 (PresbiDrops), VT-101 (Brimochol), AGN-241622, and others.
Download for updates and the latest revolution in Presbyopia care @ Presbyopia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Presbyopia Emerging Drugs Profile
LNZ100: Lenz Therapeutics
LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, a selective muscarinic receptor agonist. It works by constricting the pupil, creating a pinhole effect that improves near vision. Unlike other pupil-constricting agents, aceclidine has a unique mechanism of action that decouples the miotic effect from the stimulation of the ciliary muscle, reducing the risk of myopic shift and accompanying brow ache. This allows LNZ100 to provide a broad patient population with a long-lasting and efficient treatment for presbyopia, a condition characterized by the gradual hardening of the lens and decline in near vision with age. LNZ100 is currently in Phase III stage of its clinical trial for the treatment of presbyopia.
GLK-302: Glaukos Corporation
GLK-302 is an investigational therapy being developed by Glaukos Corporation for the treatment of presbyopia. The drug is currently being evaluated in a Phase II clinical trial as part of the company's ophthalmic pipeline, with Glaukos actively advancing its presbyopia treatment program toward later-stage development.
For more information on the Presbyopia Emerging Drugs Profile, download DelveInsight's comprehensive Presbyopia Pipeline Insight report [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Presbyopia Pipeline Report Provides
*
Detailed insights about companies developing therapies for Presbyopia, with aggregate therapies developed by each company.
*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Presbyopia treatment.
*
Presbyopia companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Presbyopia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Presbyopia market.
Learn more about Presbyopia drug opportunities in our comprehensive report @ Presbyopia Unmet Needs [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Presbyopia Companies
There are 10+ key companies, such as Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others, developing therapies for Presbyopia, with Lenz Therapeutics having its Presbyopia drug candidate in the most advanced Phase III stage.
DelveInsight's Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
*
Oral
*
Intravenous
*
Subcutaneous
*
Parenteral
*
Topical
Presbyopia products have been categorized under various molecule types such as:
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Discover the latest advancements in Presbyopia treatment @ Presbyopia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Scope of the Presbyopia Pipeline Report
*
Coverage: Global
*
Presbyopia Companies: Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.
*
Presbyopia Therapies: LX-OPH-162, Research programme, STN 1013600, GLK-302, Nyxol, VTI-001, LNZ100, MicroLine (Pilocarpine Ophthalmic), CSF-1 (PresbiDrops), VT-101 (Brimochol), AGN-241622, and others.
*
Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
*
Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Contents
1. Introduction
2. Executive Summary
3. Presbyopia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Presbyopia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. Preclinical and Discovery Stage Products
11. Inactive Products
12. Presbyopia Key Companies
13. Presbyopia Key Products
14. Presbyopia Unmet Needs
15. Presbyopia Market Drivers and Barriers
16. Presbyopia Future Perspectives and Conclusion
17. Presbyopia Analyst Views
18. Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=presbyopia-pipeline-insight-expands-as-10-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-glaukos-corporation-orasis-pharmaceuticals-novartis-cellix-bio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Presbyopia Pipeline Insight Expands as 10+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio here
News-ID: 4422806 • Views: …
More Releases from ABNewswire
Why Use Ultrasonic Transducers? Industry Trends and Best Practices
Power ultrasonic transducers (such as FUNSONIC transducers) are extensively used in the ultrasonic industry. High-quality piezoelectric ceramics generate ultrasonic waves inside the transducer, which are amplified to the device's top fee and set off vibrations in the goal medium.
The place of the piezoelectric ceramic stack is an essential component of transducer optimization design. Piezoelectric ceramics belong to the team of electroceramic materials, encompassing electrical, mechanical, and magnetic properties. Ultrasonic transducers…
G121ICE-L02 new For 12.1 inch 1280*800 LCD Screen Display
In the intricate world of electronic components and display technology, the model number G121ICE-L02 [https://www.invshop.com/g121ice-l02-new-for-121-inch-1280rgb800-lcd-screen-display-28087.html] represents more than just a part. It signifies a specific gateway to visual clarity for a wide array of devices. This article delves deep into the 12.1-inch 1280x800 LCD screen display module, exploring its technical DNA, practical applications, and the critical considerations for integration. For engineers, product developers, and procurement specialists, understanding the nuances of…
Chopped Carbon Fibers Production Line Finished Installation
During the conversion of PAN precursor to carbon fiber, the material may be chopped into short fibers (typically 3-5 mm) for use in reinforced plastics or high-temperature insulation materials.
Mechanical Cutting: Traditional method using precision rotary cutters. While effective, it can be energy-intensive and lead to mechanical damage or fraying of the fiber ends.
Laser Cutting: Recent advancements use fiber lasers to chop carbon fiber tows. This method reduces energy consumption and…
Best Law School and Bar Exam Prep Courses (2026) Report Published by Kinross Res …
Kinross Research Publishes Its Latest Research Report Recognizing Studicata as the #1 Platform Among the Best law school and bar exam prep courses.
Kinross Research today announced the publication of its latest market report, "Best law school and bar exam prep courses," now available at: https://kinrossresearch.com/best-law-school-and-bar-exam-prep-courses/
The report identifies Studicata [https://www.studicata.com/] as the #1 platform among the best law school and bar exam prep courses, citing its extensive study resources, clear explanations…
More Releases for Presbyopia
Presbyopia Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Presbyopia Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Presbyopia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Presbyopia…
Rising Geriatric Population Fuels Growth Of Myopia And Presbyopia Treatment Mark …
The Myopia and Presbyopia Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Myopia and Presbyopia Treatment Market Size and Projected Growth Rate?
The market size for myopia and presbyopia treatment has witnessed substantial growth over several recent years. The market is projected…
Myopia and Presbyopia Treatment Market: Addressing Vision Impairment Globally
The global market for myopia and presbyopia treatment has been witnessing remarkable growth, driven by the rising prevalence of vision impairment worldwide. As per recent findings from Transparency Market Research, the market was valued at approximately US$16.7 billion in 2021 and is projected to reach nearly US$45 billion by 2032, with a promising CAGR of 9.5% over the next decade. Corrective lenses emerge as the leading treatment type, with revenue…
Presbyopia Treatment Market Growth Analysis 2023-2030
Global Presbyopia Treatment Market Gains Momentum Amidst Rising Aging Population and Innovations in Therapeutics:
The global presbyopia treatment market has witnessed substantial growth in recent years, fueled by the increasing prevalence of presbyopia and the expanding aging population. Presbyopia, a common vision loss associated with aging, has prompted a surge in demand for effective treatments, leading to advancements in eyeglasses, contact lenses, surgeries, eye drops, and nutrient-based interventions.
Refractive surgeries, including Conductive…
Presbyopia Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companie …
DelveInsight's, "Presbyopia Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Presbyopia Pipeline Insight Report
• Presbyopia Pipeline report offers a comprehensive…
Presbyopia Market 2020-2027 Sets the Table for Continued Growth || Top Growing C …
A transparent research method has been accomplished with the right tools and techniques to make this Presbyopia Market research report world-class. Two of the most widely used techniques namely SWOT analysis and Porter's Five Forces Analysis have been used while generating this report. Competitive analysis conducted in this report puts light on the moves of the key players in the Healthcare industry such as new product launches, expansions, agreements, joint…
